News

RIVANNA® Announces Partnership With BOMImed to Increase Distribution of Accuro® in Canada

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with BOMImed, a recognized manufacturer of anesthesia and critical care related consumables to represent and distribute the Accuro® portfolio of products in Canada.

BOMImed is a choice distribution partner for RIVANNA as its focus is within the fields of anesthesia and critical care, with company resources dedicated to providing the highest level of service inside of these markets.

Danielle Faulk, North America Director of Sales and Distribution at RIVANNA, commented, “This strategic partnership with BOMImed will efficiently enhance Accuro’s service offerings, attract new customers and expand coverage to a more expansive range of Canadian healthcare organizations. Our growing worldwide market adoption reflects Accuro’s value to its customers. It signifies a migration away from palpation-based needle placement in favor of a safer and more efficient image-guided standard for spinal needle placement.”

The Accuro spinal navigation system is designed to improve the efficiency of spinal needle guidance procedures using groundbreaking technology, including Multi-Frequency BoneEnhance® Image Reconstruction, which provides enhanced visualization of lumbar and thoracic bony anatomy, and SpineNav3D™ AI-Based Spine Recognition, which provides automated identification of spinal midline, epidural space and depth during lumber neuraxial anesthesia. This technology also supports real-time thoracic paramedian neuraxial procedures and prescribes a “needle-track” towards the interlaminar space. Relying on automated SpineNav3D™ technology, Accuro enables users with even minimal ultrasound experience to navigate the lumbar and thoracic spine and identify relevant landmarks used to compute, visualize and pinpoint the optimal needle insertion point.

David Olivier, President and CEO of BOMImed, said, “The BOMImed team is excited to introduce Accuro’s trailblazing technology to an expanding market supporting spinal needle guidance procedures in Canada. Accuro technology and its demonstrated clinical benefits underpin our mission to stay ahead of the curve in the products we sell and enhance the lives within the anesthesia and critical care community.”

Read more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and